U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968624) titled 'Ketamine for Postherpetic Neuralgia With Depression' on April 25.
Brief Summary: This clinical trial examines the antidepressant efficacy and safety of a single low-dose intravenous esketamine combined with oral duloxetine in patients with postherpetic neuralgia and depression (duration more than 1 month). In this prospective, randomized, double-blind, placebo-controlled parallel study, eligible patients were randomized into two groups: one received esketamine plus duloxetine, and the other got placebo plus duloxetine. Both groups underwent standard pain management and neuro modulation therapy. The primary outcome was the Hospital An...